Home | Articles
Published on:December 2019
Indian Journal of Pharmaceutical Education and Research, 2020; 54(1):73-84
Original Article | doi:10.5530/ijper.54.1.9

Direct Brain Targeted Nanostructured Lipid Carriers for Sustained Release of Schizophrenic Drug: Formulation, Characterization and Pharmacokinetic Studies

Authors and affiliation (s):

Praveen Sivadasu1, Devagowda Vishakante Gowda1,*, Nithin Kundachira Subramani2, Bhavya Malgur Vishweshwaraiah1, Sachhidananda Shivanna3, Siddaramaiah Hatna3

1Department of Pharmaceutics, JSS College of Pharmacy, JSSAHER, Mysuru, Karnataka, INDIA.

2Department of Chemistry, The National Institute of Engineering, Mysuru, Karnataka, INDIA.

3Department of Polymer science and Technology, Sri Jayachamarajendra College of Engineering, Mysuru, Karnataka, INDIA.


Background: Systemic drug delivery in schizophrenia is a major challenge, owing to the Blood-brain Barrier (BBB) and P-glycoprotein related effects. Consequently, herein an attempt is made to systemically deliver the most desirable schizophrenia drug, Quetiapine Fumarate (QF) via non-invasive intranasal route using Nanostructured Lipid Carrier (NLC) approach. Materials and Methods: The desired QF loaded NLCs were developed using central composite statistical design and the developed formulations were monitored for improving QF bioavailability and their brain targeting efficacies. Results: The optimized formulation displayed a 2-fold increase (compared to virgin QF) in ex-vivo nasal diffusion at the 6th hr, with no sign of structural damage (upon histopathological examinations). While, QF blood-brain ratio showed 10-fold increase for NLCs administered through nasal route (in comparison to intravenous route), thereby supporting prolonged retention of QF at the site of action. Similarly, the concentration of QF (in the brain) delivered via nasal route exhibited 4-fold increment at all-time points thereby supporting a potential nose to brain transport and effective bypassing of BBB. Conclusion: The results obtained infers that non-invasive intranasal route can be used as a potential alternative to conventional treatment options towards efficient management of schizophrenia.

Key words: Nanostructured lipid carriers, Quetiapine fumarate, Schizophrenia, Brain Targeting, Intranasal route.



Impact Factor

IJPER - An Official Publication of Association of Pharmaceutical Teachers of India is pleased to announce continued growth in the 2019 Release of Journal Citation Reports (source: 2018 Web of Science Data).


Impact Factor® as reported in the 2018 Journal Citation Reports® (Clarivate Analytics, 2019): 0.425

User login

The Official Journal of Association of Pharmaceutical Teachers of India (APTI)
(Registered under Registration of Societies Act XXI of 1860 No. 122 of 1966-1967, Lucknow)

Indian Journal of Pharmaceutical Education and Research (IJPER) [ISSN-0019-5464] is the official journal of Association of Pharmaceutical Teachers of India (APTI) and is being published since 1967.


IJPER uses reference linking service using Digital Object Identifiers (DOI) by Crossref. Articles from the year 2013 are being assigned DOIs for its permanent URLs